CSTONE PHARMA-B Shares Climb Over 4% on Triple Pipeline Recognition at Prestigious Cancer Conference

Stock News

03/24

CStone Pharmaceuticals-B (02616) rose more than 4%. At the time of writing, the stock was up 3.05%, trading at HK$6.41 with a turnover of HK$18.1843 million. The increase follows recent news that the company announced preclinical research results from three of its self-developed drug pipelines have been successfully selected for the poster presentation session at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). This conference is one of the most influential academic gatherings in the global field of cancer research. The 2026 annual meeting is scheduled to be held from April 17 to April 22, 2026, at the San Diego Convention Center in California, USA. Related research abstracts will be published on April 3, 2026, in the AACR's official journal, *Cancer Research*.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1152835973"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152835973\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152835973?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152835973","market":"hk","top_or_hot":-1,"title":"CSTONE PHARMA-B Shares Climb Over 4% on Triple Pipeline Recognition at Prestigious Cancer Conference","media":"Stock News","content":"<p>CStone Pharmaceuticals-B (02616) rose more than 4%. At the time of writing, the stock was up 3.05%, trading at HK$6.41 with a turnover of HK$18.1843 million.\nThe increase follows recent news that the company announced preclinical research results from three of its self-developed drug pipelines have been successfully selected for the poster presentation session at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). This conference is one of the most influential academic gatherings in the global field of cancer research. The 2026 annual meeting is scheduled to be held from April 17 to April 22, 2026, at the San Diego Convention Center in California, USA. Related research abstracts will be published on April 3, 2026, in the AACR's official journal, *Cancer Research*.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSTONE PHARMA-B Shares Climb Over 4% on Triple Pipeline Recognition at Prestigious Cancer Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSTONE PHARMA-B Shares Climb Over 4% on Triple Pipeline Recognition at Prestigious Cancer Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-24 10:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CStone Pharmaceuticals-B (02616) rose more than 4%. At the time of writing, the stock was up 3.05%, trading at HK$6.41 with a turnover of HK$18.1843 million.\nThe increase follows recent news that the company announced preclinical research results from three of its self-developed drug pipelines have been successfully selected for the poster presentation session at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). This conference is one of the most influential academic gatherings in the global field of cancer research. The 2026 annual meeting is scheduled to be held from April 17 to April 22, 2026, at the San Diego Convention Center in California, USA. Related research abstracts will be published on April 3, 2026, in the AACR's official journal, *Cancer Research*.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1152835973","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152835973","pubTimestamp":1774319068,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CStone Pharmaceuticals-B (02616) rose more than 4%. At the time of writing, the stock was up 3.05%, trading at HK$6.41 with a turnover of HK$18.1843 million. The increase follows recent news that the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","02616":"基石药业-B","VXUS":"国际股票ETF-Vanguard","BK1574":"生物医药B类股","BK4588":"碎股","BK1161":"生物科技"},"translate_title":"基石药业-B股价因三重管道在著名癌症会议上获得认可而上涨超过4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02616":1},"content_text":"CStone Pharmaceuticals-B (02616) rose more than 4%. At the time of writing, the stock was up 3.05%, trading at HK$6.41 with a turnover of HK$18.1843 million.\nThe increase follows recent news that the company announced preclinical research results from three of its self-developed drug pipelines have been successfully selected for the poster presentation session at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). This conference is one of the most influential academic gatherings in the global field of cancer research. The 2026 annual meeting is scheduled to be held from April 17 to April 22, 2026, at the San Diego Convention Center in California, USA. Related research abstracts will be published on April 3, 2026, in the AACR's official journal, *Cancer Research*.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}